Alzheimer's Drugs Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class and End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Description

List of Tables

The Alzheimer's drugs market size is expected to grow from US$ 8.24 billion in 2024 to US$ 26.37 billion by 2031; it is projected to register a CAGR of 13.6% during 2025-2031. The aging population & rising Alzheimer's prevalence, and improved diagnostics & early detection are noteworthy factors contributing to the expansion of the Alzheimer's drugs market size. However, the high cost of disease-modifying therapies hinders the Alzheimer's drugs market.

Public-private partnerships and funding leverage the resources of government organizations, academic centers, pharmaceutical firms, and philanthropic foundations to speed up the creation of effective treatments. The US National Institutes of Health (NIH)'s Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD 2.0) has attracted a substantial number of resources to drive research on Alzheimer's. This initiative integrates more than US$61 million of public investment from the NIH with investment from pharmaceutical firms like Eisai and Takeda. This project promotes open sharing of data and precision medicine strategies, accelerating biomarker discovery and validation of therapeutic targets. Philanthropic initiatives like BrightFocus and Part the Cloud have invested millions in early-stage research, backing forward-thinking projects which have secured more than a billion dollars in funding from multiple sources, ranging from venture capital to pharma partnerships. At the state level, the proposed Texas Dementia Prevention and Research Institute of Texas (DPRIT) would commit up to US$3 billion over ten years to dementia research, fostering collaborations that might spur local biotech expansion and clinical breakthroughs. Furthermore, partnerships among big pharma and biotechs are on the rise, such as with Biogen in partnership with Eisai to co-develop and market Alzheimer's therapies, pooling resources and capabilities to drive faster entry into markets. These public-private initiatives mitigate financial risks and enhance resource sharing, de-risking drug development, and compress timelines. Commercially, they diversify the Alzheimer's drugs pipeline, stimulate investment from biotech and pharma, and boost regulatory and public trust in new medicines. These partnerships and funding influxes are accelerating disease-modifying treatments and underpinning a more innovation-driven Alzheimer's drugs market.

End User-Based Insights

Based on end user, the Alzheimer's drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest Alzheimer's drugs market share in 2024. Particularly in areas where hospital-based care is the main method of diagnosis and treatment initiation, hospital pharmacies distribute and oversee AD medications. Hospital pharmacies are essential resources for prescribing, dispensing, and advising patients and caregivers on therapeutic options due to the complexity of managing Alzheimer's disease, which calls for specialized neurologists or geriatricians. The sale of Alzheimer's medications in hospital pharmacies is influenced by reimbursement regulations and changing treatment recommendations. Hospitals continue to prescribe ChEIs as the first-line symptomatic treatments for mild to moderate AD. Because of its demonstrated effectiveness and tolerability, donepezil (Aricept), the most prescribed ChEI worldwide, is included in hospital formularies. Rivastigmine provides the dosing flexibility preferred in hospital settings where patient monitoring is practical. It is available as oral capsules and transdermal patches. Hospital pharmacies add value by providing medication counseling, adherence monitoring, and managing side effects-services critical in Alzheimer's treatment. Such programs differentiate hospital pharmacy offerings from retail outlets and support patient outcomes, potentially driving demand for specific formulations (e.g., rivastigmine patches for better compliance), thereby fueling the Alzheimer's drugs market growth.

The World Health Organization and Medicare are among the primary and secondary sources referred to while preparing the Alzheimer's drugs market report.

Product Code: TIPRE00015800

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Alzheimer's Drugs Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Alzheimer's Drugs Market - Key Market Dynamics

5.1 Alzheimer's Drugs Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Aging Population & Rising Alzheimer's Prevalence
- 5.2.2 Improved Diagnostics & Early Detection
5.3 Market Restraints
- 5.3.1 High Cost of Disease-Modifying Therapies (DMTs)
5.4 Market Opportunities
- 5.4.1 Combination Therapies and Adjunct Treatments
5.5 Future Trends
- 5.5.1 Public-Private Collaborations and Funding Growth
5.6 Impact of Drivers and Restraints:

6. Alzheimer's Drugs Market - Global Market Analysis

6.1 Alzheimer's Drugs Market Revenue (US$ Million), 2021-2031
6.2 Alzheimer's Drugs Market Forecast Analysis

7. Alzheimer's Drugs Market Analysis - by Drug Class

7.1 Cholinesterase Inhibitors
- 7.1.1 Overview
- 7.1.2 Cholinesterase Inhibitors: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.2 NMDA Receptor Antagonists
- 7.2.1 Overview
- 7.2.2 NMDA Receptor Antagonists: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Combination Drugs
- 7.3.1 Overview
- 7.3.2 Combination Drugs: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Alzheimer's Drugs Market Analysis - by End User

8.1 Hospital Pharmacies
- 8.1.1 Overview
- 8.1.2 Hospital Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Retail Pharmacies
- 8.2.1 Overview
- 8.2.2 Retail Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Online Pharmacies
- 8.3.1 Overview
- 8.3.2 Online Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Alzheimer's Drugs Market - Geographical Analysis

9.1 Overview
9.2 North America
- 9.2.1 North America Alzheimer's Drugs Market Overview
- 9.2.2 North America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  - 9.2.2.1 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 9.2.2.1.1 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
  - 9.2.2.2 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
- 9.2.3 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
  - 9.2.3.1 United States: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.2.3.1.1 United States: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.2.3.1.1.1 United States: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.2.3.1.2 United States: Alzheimer's Drugs Market Breakdown, by End User
  - 9.2.3.2 Canada: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.2.3.2.1 Canada: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.2.3.2.1.1 Canada: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.2.3.2.2 Canada: Alzheimer's Drugs Market Breakdown, by End User
  - 9.2.3.3 Mexico: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.2.3.3.1 Mexico: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.2.3.3.1.1 Mexico: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.2.3.3.2 Mexico: Alzheimer's Drugs Market Breakdown, by End User
9.3 Europe
- 9.3.1 Europe Alzheimer's Drugs Market Overview
- 9.3.2 Europe: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  - 9.3.2.1 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 9.3.2.1.1 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
  - 9.3.2.2 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
- 9.3.3 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
  - 9.3.3.1 Germany: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.3.3.1.1 Germany: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.3.3.1.1.1 Germany: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.3.3.1.2 Germany: Alzheimer's Drugs Market Breakdown, by End User
  - 9.3.3.2 United Kingdom: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.3.3.2.1 United Kingdom: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.3.3.2.1.1 United Kingdom: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.3.3.2.2 United Kingdom: Alzheimer's Drugs Market Breakdown, by End User
  - 9.3.3.3 France: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.3.3.3.1 France: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.3.3.3.1.1 France: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.3.3.3.2 France: Alzheimer's Drugs Market Breakdown, by End User
  - 9.3.3.4 Italy: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.3.3.4.1 Italy: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.3.3.4.1.1 Italy: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.3.3.4.2 Italy: Alzheimer's Drugs Market Breakdown, by End User
  - 9.3.3.5 Spain: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.3.3.5.1 Spain: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.3.3.5.1.1 Spain: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.3.3.5.2 Spain: Alzheimer's Drugs Market Breakdown, by End User
  - 9.3.3.6 Rest of Europe: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.3.3.6.1 Rest of Europe: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.3.3.6.1.1 Rest of Europe: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.3.3.6.2 Rest of Europe: Alzheimer's Drugs Market Breakdown, by End User
9.4 Asia Pacific
- 9.4.1 Asia Pacific Alzheimer's Drugs Market Overview
- 9.4.2 Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  - 9.4.2.1 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 9.4.2.1.1 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
  - 9.4.2.2 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
- 9.4.3 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
  - 9.4.3.1 China: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.4.3.1.1 China: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.4.3.1.1.1 China: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.4.3.1.2 China: Alzheimer's Drugs Market Breakdown, by End User
  - 9.4.3.2 Japan: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.4.3.2.1 Japan: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.4.3.2.1.1 Japan: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.4.3.2.2 Japan: Alzheimer's Drugs Market Breakdown, by End User
  - 9.4.3.3 India: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.4.3.3.1 India: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.4.3.3.1.1 India: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.4.3.3.2 India: Alzheimer's Drugs Market Breakdown, by End User
  - 9.4.3.4 Australia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.4.3.4.1 Australia: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.4.3.4.1.1 Australia: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.4.3.4.2 Australia: Alzheimer's Drugs Market Breakdown, by End User
  - 9.4.3.5 South Korea: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.4.3.5.1 South Korea: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.4.3.5.1.1 South Korea: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.4.3.5.2 South Korea: Alzheimer's Drugs Market Breakdown, by End User
  - 9.4.3.6 Rest of APAC: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.4.3.6.1 Rest of APAC: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.4.3.6.1.1 Rest of APAC: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.4.3.6.2 Rest of APAC: Alzheimer's Drugs Market Breakdown, by End User
9.5 Middle East and Africa
- 9.5.1 Middle East and Africa Alzheimer's Drugs Market Overview
- 9.5.2 Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  - 9.5.2.1 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 9.5.2.1.1 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
  - 9.5.2.2 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
- 9.5.3 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
  - 9.5.3.1 Saudi Arabia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.5.3.1.1 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.5.3.1.1.1 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.5.3.1.2 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by End User
  - 9.5.3.2 South Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.5.3.2.1 South Africa: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.5.3.2.1.1 South Africa: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.5.3.2.2 South Africa: Alzheimer's Drugs Market Breakdown, by End User
  - 9.5.3.3 United Arab Emirates: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.5.3.3.1 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.5.3.3.1.1 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.5.3.3.2 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by End User
  - 9.5.3.4 Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.5.3.4.1 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.5.3.4.1.1 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.5.3.4.2 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by End User
9.6 South and Central America
- 9.6.1 South and Central America Alzheimer's Drugs Market Overview
- 9.6.2 South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  - 9.6.2.1 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
    - 9.6.2.1.1 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
  - 9.6.2.2 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
- 9.6.3 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
  - 9.6.3.1 Brazil: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.6.3.1.1 Brazil: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.6.3.1.1.1 Brazil: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.6.3.1.2 Brazil: Alzheimer's Drugs Market Breakdown, by End User
  - 9.6.3.2 Argentina: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.6.3.2.1 Argentina: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.6.3.2.1.1 Argentina: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.6.3.2.2 Argentina: Alzheimer's Drugs Market Breakdown, by End User
  - 9.6.3.3 Rest of South and Central America: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.6.3.3.1 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by Drug Class
      - 9.6.3.3.1.1 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
    - 9.6.3.3.2 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by End User

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players
10.2 Company Market Share Analysis, 2024

11. Industry Landscape

11.1 Overview
11.2 New Product Development and Approvals
11.3 Partnerships
11.4 Other Business Strategies

12. Company Profiles

12.1 Novartis AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Daiichi Sankyo Co Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Johnson & Johnson
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Pfizer Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Merck & Co Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Biogen Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Merz Pharma GmbH & Co KGaA
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Eli Lilly and Co
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Otsuka Pharmaceuticals Co Ltd
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 AbbVie Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms